Lemborexant to Remain Monitored as a TPP Type 2 Medication

Written By CPSA

The Alberta TPP Steering Committee has decided to continue to monitor lemborexant as a TPP Type 2 medication. This decision follows 12 months of initial observation and evaluation.

For any questions or more information, please email us at TPP.Info@cpsa.ab.ca.

CPSA
Next

Extension of PrescribeIT Exemption